Trial of an Interactive CD-Program on 6 Months Readmission Rate in Patients With Heart Failure
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Educational/Counseling/Training
|Official Title:||A Randomised, Controlled Trial of an Interactive CD-Program on 6 Months Readmission Rate in Patients With Heart Failure|
- Readmission and death rate at 6 months' follow up.
- Knowledge regarding heart failure and its treatment
|Study Start Date:||February 1998|
|Estimated Study Completion Date:||July 2002|
The prevalence of heart failure (HF) has increased in the western world and is a major concern due to increasing prevalence and rising health care costs. The prognosis remains poor despite improvement in survival due to treatment with ACE-inhibitors and beta-receptor antagonists. HF has a high rate of readmission and hospitalisation. Some readmissions are ascribed to patients’ lack of compliance, insufficient knowledge about diet, medication and symptoms of heart failure. Education of patients has become an important component in order to increase the patients’ self-care and compliance. Intense education and counselling of patients is recommended in both European and American guidelines for HF.
Several systematic reviews of studies on strategies for improvement of outcomes of heart failure patients after discharge have been published, but very little emphasis has been put on methodological issues, e.g. methods of education. In most programs the methods and equipment used for education and information have only consisted of verbal and written material; computer-based tools seem to be relatively new.
Interactive CD-ROM programs for HF patients can increase patients’ knowledge about heart failure and its treatment. However, no studies have examined the clinical outcome, e.g. rate of readmission.
Comparison: Extra educated patients (interactive CD-ROM education) compared to standard educated patients on readmission rate or death during 6 months.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00311194
|Drug and Therapeutics Committee, Malmoe University Hospital|
|Malmo, Sweden, S-205 02|
|Study Director:||Hans Liedholm, MD, PhD||Drug and Therapeutics Committee|
|Study Chair:||Agneta Björck Linné, B Pharm, PhD||Drug and Therapeutics Committee|